Press coverage about Innocoll (NASDAQ:INNL) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Innocoll earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 44.3359195645833 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Innocoll (NASDAQ INNL) traded up $0.11 on Thursday, hitting $2.35. 392,900 shares of the stock were exchanged, compared to its average volume of 867,012. The company has a debt-to-equity ratio of -2.26, a current ratio of 1.01 and a quick ratio of 0.86. Innocoll has a 1-year low of $0.53 and a 1-year high of $6.51.
Innocoll Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.
Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with MarketBeat.com's FREE daily email newsletter.